Sermorelin Pharmacogenomics & Genetic Variability: What Your DNA Means for Growth Hormone Response

HealthRX.com

No DNA test yet predicts how you respond to sermorelin

Print or save as PDF

Key numbers

  • 8.0 cm/yrMean height velocity at 6 months in children with growth hormone deficiency, up from 4.1 cm/yr at baselineSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 30 micrograms per kgSubcutaneous bedtime dose given to 110 prepubertal children with growth hormone deficiency in the pediatric trialSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1 mgTwice-daily dose at which 24-hour GH and IGF-I rose significantly in 10 healthy men with a mean age of 68Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Sermorelin

  • Drug / sermorelin acetate, a 29-amino-acid GHRH analogue given by subcutaneous injection [2]
  • FDA status / Geref discontinued in 2008, approvals withdrawn June 18, 2009; no sermorelin product approved today [3]
  • Approved uses when Geref existed / pediatric growth hormone deficiency and a pituitary diagnostic test only [3]
  • Pediatric response / 110 children enrolled, 86 evaluable, 74% good responders at 6 months [1]
  • Dose effect in older men / GH and IGF-I rose significantly at 1 mg twice daily but not significantly at 0.5 mg twice daily [4]
  • GH versus IGF-I / nocturnal GH rose but IGF-I did not in 11 men given 2 mg nightly for 6 weeks [5]
  • Sport / named by WADA, prohibited at all times [6]

Does DNA change how you respond to sermorelin?

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH) that acts on the pituitary's GHRH receptor to make the body release its own growth hormone; it is not growth hormone itself [2]. The available sermorelin studies report group results, not genotype-based results, so no DNA-guided dose or response prediction has been established.

Questions worth asking

Choose the questions you want to keep

What the pediatric trial measured

The Geref International Study Group treated 110 previously untreated prepubertal children with growth hormone deficiency with 30 micrograms per kg subcutaneously at bedtime for up to a year; 86 were evaluable. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were good responders at 6 months [1].

What the older-adult studies measured

Dose effects have been measured in small physiology studies. Ten healthy men with a mean age of 68 took 0.5 mg and 1 mg of GHRH(1-29) subcutaneously twice daily for 14 days each, in random order, and were compared with nine men of mean age 26. At the high dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the younger men's; the rises were significant only at that dose [4]. This was a short physiology study, not a trial of clinical benefit.

Growth hormone and IGF-I also do not always move together. Eleven men aged 64 to 76 injected 2 mg nightly for 6 weeks; nocturnal growth hormone release rose (P<0.02 for mean nocturnal GH), while IGF-I, IGFBP-3 and GH binding protein did not change [5].

Is there an approved dose to work from?

No sermorelin product is currently FDA-approved, so there is no current approved dose [3]. Geref was approved for two uses only: treating idiopathic growth hormone deficiency in children with growth failure, and testing the pituitary's ability to secrete growth hormone [3]. It was not approved for adults, anti-aging, weight loss or athletic performance [3]. The maker discontinued it in 2008, FDA withdrew both approvals effective June 18, 2009, and FDA later determined the drug was not withdrawn for reasons of safety or effectiveness [3].

Sermorelin sold in the US today is compounded, and compounded drugs are not FDA-approved; FDA does not review their safety, effectiveness or quality before they are marketed [7].

Safety and sports status

In the 1-year pediatric study, no adverse changes were seen in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and sermorelin was well tolerated overall [1]. Athletes should know that WADA's Prohibited List names sermorelin under growth hormone releasing factors (S2.2.4) and prohibits it at all times, in and out of competition [6].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. In the pediatric trial that anchors sermorelin's evidence, what share of children were good responders at 6 months?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is there a genotype-based dose of sermorelin?
There is no current approved sermorelin dose to guide by genotype, because no sermorelin product is FDA-approved today [3]. In the pediatric study the dose used was 30 micrograms per kg once daily subcutaneously at bedtime [1].
Does the dose change the response?
In 10 healthy men with a mean age of 68, 24-hour growth hormone and IGF-I rose significantly at 1 mg twice daily but not significantly at 0.5 mg twice daily [4].
Does growth hormone rising on a blood test mean IGF-I rises too?
Not necessarily. In 11 men aged 64 to 76 given 2 mg nightly for 6 weeks, nocturnal growth hormone release increased but IGF-I, IGFBP-3 and GH binding protein did not change [5].
Is sermorelin FDA-approved?
No. Geref was approved for pediatric growth hormone deficiency treatment and a pituitary diagnostic test; the maker discontinued it in 2008 and FDA withdrew the approvals in 2009 [3]. Sermorelin sold today is compounded and not FDA-approved [7].
Show all 7 referencesHide references
  1. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  2. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
  3. Federal Register :: Request Access.
  4. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
  5. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
  6. World Anti-Doping Agency.
  7. Official web page.
Sermorelin pharmacogenomics: evidence summary chart
Image: HealthRX.com. Full sermorelin pharmacogenomics guide and sources at healthrx.com/sermorelin.